Surgical & Medical Instruments & ApparatusSIC 3841
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Profound Medical Corp. filings on SEC EDGAR ↗
For the nine months ended September 30, 2026, Profound Medical Corp. reported total revenue of $17.65 million, a significant increase from $10.12 million in the prior year, driven largely by capital equipment sales. Despite the revenue growth, the company recorded a net loss of $24.32 million, though this was an improvement over the $34.40 million loss in the same period of 2025.
Profound Medical reported Q3 2026 revenue of $9.8 million, an 86% year-over-year increase, driven by strong capital equipment sales and recurring revenue. The company achieved a 78% gross margin and significantly reduced its operating cash use by 56% sequentially. Additionally, the company announced a leadership transition with Richard Fabian appointed as CEO effective January 2027.
Term
Q3 2026
“Revenue increased 86% year-over-year, gross margin reached 78%, and operating cash use declined substantially from the second quarter. These results, together with our commercial pipeline, support our strong full-year outlook. Our priority is to convert growing physician interest, broader payer coverage and clinical evidence into system placements and recurring procedure revenue.”
Arun Menawat, Profound’s Chief Executive Officer and Chairman
“Our new Cook Medical agreement adds a key U.S. distribution channel, complementing our own sales team’s continued focus on selling TULSA-PRO for existing 1.5T and 3.0T MRI systems outside the agreement’s scope, while preserving our direct relationships for disposables and service. With experienced leadership in place and continued investment in product efficiency, we are positioning Profound to scale toward profitable growth.”
Arun Menawat, Profound’s Chief Executive Officer and Chairman